Avidity Biosciences's total assets for Q3 2024 were $1.64B, an increase of 21.77% from the previous quarter. RNA total liabilities were $137.39M for the fiscal quarter, a 8.70% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.